Congenital Hyperinsulinism Treatment Market
Market Insights on Congenital Hyperinsulinism Treatment covering sales outlook, demand forecast & up-to-date key trends
Congenital Hyperinsulinism Treatment Market By Treatment Method, Application & Region | Forecast 2023 to 2033
Congenital Hyperinsulinism Treatment Market Snapshot (2023 to 2033)
The global congenital hyperinsulinism treatment market is expected to garner a market value of US$ 100 Million in 2023 and is expected to accumulate a market value of US$ 179.08 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Congenital Hyperinsulinism registered a CAGR of 4% in the historical period 2017 to 2022.
Diabetes is a most common health problem causing high blood sugar levels resulting in excessive thirst and large amounts of urine production. It causes secondary health-associated problems such as diabetic ketoacidosis, hyperosmolar hyperglycemic states, and other serious complications (heart attack, stroke, kidney failure, leg amputation) leading to premature death.
The growing number of patients suffering from diabetes will accelerate the market growth rate. Moreover, increasing awareness among physicians and patients about the benefits of Congenital Hyperinsulinism will provide beneficial opportunities for the growth of the Congenital Hyperinsulinism Treatment market.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 100 Million |
|
Anticipated Forecast Value (2033) |
US$ 179.08 Million |
|
Projected Growth Rate (2023 to 2033) |
6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2017 to 2022 Congenital Hyperinsulinism Treatment Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Congenital Hyperinsulinism reflected a value of 4% during the historical period, 2017 to 2022. Various factors such as awareness of wellness and health and the rising geriatric population suffering from diabetes are projected to drive the market growth.
In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Congenital Hyperinsulinism treatment is fuelling the market growth. Thus, the market for Congenital Hyperinsulinism is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of the Congenital Hyperinsulinism Treatment Market?
Strong Relation Between Diabetes & Congenital Hyperinsulinism to push the market growth
The increasing prevalence of Congenital Hyperinsulinism disease is one of the biggest drivers of the market. As per studies, Congenital hyperinsulinism affects approximately 1 in 50,000 newborns. This condition is more common in certain populations, affecting up to 1 in 2,500 newborns. Furthermore, studies suggest that about 60% of babies with HI are diagnosed during the first month of life. An additional 30% will be diagnosed later in the first year and the remainder after that. With early treatment and aggressive prevention of hypoglycemia, brain damage can be prevented. However, brain damage can occur in children with HI if the condition is not recognized or if treatment is ineffective in the prevention of hypoglycemia.
The massive growth in the diabetic population is primarily attributable to rising Congenital Hyperinsulinism rates around the world, as well as sedentary lifestyles defined by poor diets and decreased physical exercise.
Furthermore, a strong relationship between diabetes and Congenital Hyperinsulinism has been proven by certain studies. For instance, NCBI states that β cell failure in type 2 diabetes (T2D) is associated with hyperglycemia, but the mechanisms are not fully understood. Congenital hyperinsulinism caused by glucokinase mutations (GCK-CHI) is associated with β cell replication and apoptosis. Here, we show that genetic activation of β cell glucokinase, initially triggering replication, causes apoptosis associated with DNA double-strand breaks and activation of the tumor suppressor p53.
Considering these in-depth studies, the market is projected to show considerable growth through 2033.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the Congenital Hyperinsulinism Treatment Market?
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Congenital Hyperinsulinism, less awareness of Congenital Hyperinsulinism disease, and insubstantial treatment options are hampering the market growth.
Region-Wise Insights
How is the Market for Congenital Hyperinsulinism Treatment Turning Out in the Asia Pacific Region?
Improvement in healthcare spending propelling growth of Congenital Hyperinsulinism in Asia Pacific
The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of Congenital Hyperinsulinism treatment in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the treatment market worldwide.
What are the Factors Boosting the Market for Congenital Hyperinsulinism in North America?
Technological Advancements Shaping Landscape for Congenital Hyperinsulinism in North America
North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. Furthermore, due to the presence of leading technological advancements in the healthcare sector and healthcare facilities with the advancements in technology, efficient treatments are being introduced.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Category-Wise Insights
By Application, Which End-User is Likely to Account for the Highest Share?
Hospitals to take the lead and drive market growth
The application segment has been divided into hospitals, retail pharmacies, and Ambulatory Surgical Centres. According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during Congenital Hyperinsulinism treatment facilitates the growth of this segment.
Start-ups in the Congenital Hyperinsulinism Treatment Market
Key start-up players in the Congenital Hyperinsulinism Treatment Market are-
- Xinvento, a biotech company aiming to improve the lives of those with Congenital Hyperinsulinism, announced the completion of a seed funding round. Xinvento was founded in 2021 by CEO Claudine van der Sande, the driving force behind the company, who has a son diagnosed with Congenital Hyperinsulinism (CHI). This seed funding will enable Xinvento to design and test its proprietary molecules in the relevant pre-clinical models to identify potential drug candidates.
- Rezolute (formerly Antriabio) is a biopharmaceutical company, developing drugs for metabolic and orphan diseases. The lead candidate, RZ358 is an insulin receptor antagonist monoclonal antibody for congenital hyperinsulinism (CHI) and has an orphan drug designation(Phase 2). Another molecule, AB101 is a once-weekly injectable basal insulin for diabetes management (in Phase 1). Also developing plasma kallikrein inhibitors (PKI) for diabetic macular edema (DME) & hereditary angioedema (HAE). In Dec 2017, the company entered into a license agreement with Xoma which gives Rezolute exclusive global rights to develop and commercialize RZ358, formerly called XOMA 358.
Market Competition
Key players in the Congenital Hyperinsulinism Treatment Market are Eli Lilly, Novo Nordisk, Novartis AG, Rezolute, Inc., Eiger BioPharmaceuticals., Zealand Pharma A/S, Hanmi Pharmaceutical Co., Ltd., Crinetics Pharmaceuticals, Inc., AmideBio LLC, and Xeris Pharmaceuticals, Inc.
- In September 2022, Novo Nordisk and Microsoft entered a new strategic collaboration to combine Microsoft’s computational services, cloud, and artificial intelligence (AI) with Novo Nordisk’s drug discovery, development, and data science capabilities. Through the partnership, Microsoft is providing AI technology, foundational science models, and expertise and is working alongside Novo Nordisk’s data scientists and domain experts from early research and development areas to accelerate Novo Nordisk’s Research and Development.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 100 Million |
|
Market Value in 2033 |
US$ 179.08 Million |
|
Growth Rate |
CAGR of 6% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2017 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
Eli Lilly, Novo Nordisk, Novartis AG, Rezolute, Inc., Eiger BioPharmaceuticals., Zealand Pharma A/S, Hanmi Pharmaceutical Co., Ltd., Crinetics Pharmaceuticals, Inc., AmideBio LLC, Xeris Pharmaceuticals, Inc |
|
Customization |
Available Upon Request |
Key Segments Profiled in the Congenital Hyperinsulinism Industry Survey
Treatment Method:
- Drug Therapy
- Diazoxide
- Octreotide
- Glucagon
- Others
- Surgery
Application:
- Hospitals
- Clinics
- Others
Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa(MEA)
Frequently Asked Questions
At what rate did the Congenital Hyperinsulinism Treatment Market flourish from 2017 to 2022?
From 2017 to 2022, the Congenital Hyperinsulinism Treatment Market grew at a CAGR of 4%.
What will be the growth rate of the global Congenital Hyperinsulinism Treatment Market during the forecast period?
The global Congenital Hyperinsulinism Treatment Market is expected to grow with a 6% CAGR from 2023 to 2033.
What will be the projected market size of the Congenital Hyperinsulinism Treatment Market by 2033?
As of 2033, the Congenital Hyperinsulinism Treatment Market is expected to reach US$ 179.08 Million
Which End-Use segment is expected to dominate the global Congenital Hyperinsulinism Treatment Market during 2033?
According to the FMI analysis, hospitals account for the largest market share.
How is the North America Congenital Hyperinsulinism Treatment Market projected to grow in 2033?
North America is expected to possess a 25% market share in the Congenital Hyperinsulinism Treatment Market.
How is the Asia Pacific Congenital Hyperinsulinism Treatment Market projected to grow in 2033?
The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
Table of Content
1. Executive Summary | Congenital Hyperinsulinism Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Methods 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Methods, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Methods, 2023 to 2033 5.3.1. Drug Therapy 5.3.1.1. Diazoxide 5.3.1.2. Octreotide 5.3.1.3. Glucagon 5.3.1.4. Others 5.3.2. Surgery 5.4. Y-o-Y Growth Trend Analysis By Treatment Methods, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment Methods, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033 6.3.1. Hospitals 6.3.2. Clinics 6.3.3. Others 6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. Asia Pacific 7.3.5. Middle East and Africa(MEA) 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Treatment Methods 8.2.3. By Application 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Treatment Methods 8.3.3. By Application 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Treatment Methods 9.2.3. By Application 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment Methods 9.3.3. By Application 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Treatment Methods 10.2.3. By Application 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment Methods 10.3.3. By Application 10.4. Key Takeaways 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. China 11.2.1.2. Japan 11.2.1.3. South Korea 11.2.1.4. Singapore 11.2.1.5. Thailand 11.2.1.6. Indonesia 11.2.1.7. Australia 11.2.1.8. New Zealand 11.2.1.9. Rest of Asia Pacific 11.2.2. By Treatment Methods 11.2.3. By Application 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment Methods 11.3.3. By Application 11.4. Key Takeaways 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. GCC Countries 12.2.1.2. South Africa 12.2.1.3. Israel 12.2.1.4. Rest of Middle East and Africa(MEA) 12.2.2. By Treatment Methods 12.2.3. By Application 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment Methods 12.3.3. By Application 12.4. Key Takeaways 13. Key Countries Market Analysis 13.1. USA 13.1.1. Pricing Analysis 13.1.2. Market Share Analysis, 2022 13.1.2.1. By Treatment Methods 13.1.2.2. By Application 13.2. Canada 13.2.1. Pricing Analysis 13.2.2. Market Share Analysis, 2022 13.2.2.1. By Treatment Methods 13.2.2.2. By Application 13.3. Brazil 13.3.1. Pricing Analysis 13.3.2. Market Share Analysis, 2022 13.3.2.1. By Treatment Methods 13.3.2.2. By Application 13.4. Mexico 13.4.1. Pricing Analysis 13.4.2. Market Share Analysis, 2022 13.4.2.1. By Treatment Methods 13.4.2.2. By Application 13.5. Germany 13.5.1. Pricing Analysis 13.5.2. Market Share Analysis, 2022 13.5.2.1. By Treatment Methods 13.5.2.2. By Application 13.6. United Kingdom 13.6.1. Pricing Analysis 13.6.2. Market Share Analysis, 2022 13.6.2.1. By Treatment Methods 13.6.2.2. By Application 13.7. France 13.7.1. Pricing Analysis 13.7.2. Market Share Analysis, 2022 13.7.2.1. By Treatment Methods 13.7.2.2. By Application 13.8. Spain 13.8.1. Pricing Analysis 13.8.2. Market Share Analysis, 2022 13.8.2.1. By Treatment Methods 13.8.2.2. By Application 13.9. Italy 13.9.1. Pricing Analysis 13.9.2. Market Share Analysis, 2022 13.9.2.1. By Treatment Methods 13.9.2.2. By Application 13.10. China 13.10.1. Pricing Analysis 13.10.2. Market Share Analysis, 2022 13.10.2.1. By Treatment Methods 13.10.2.2. By Application 13.11. Japan 13.11.1. Pricing Analysis 13.11.2. Market Share Analysis, 2022 13.11.2.1. By Treatment Methods 13.11.2.2. By Application 13.12. South Korea 13.12.1. Pricing Analysis 13.12.2. Market Share Analysis, 2022 13.12.2.1. By Treatment Methods 13.12.2.2. By Application 13.13. Singapore 13.13.1. Pricing Analysis 13.13.2. Market Share Analysis, 2022 13.13.2.1. By Treatment Methods 13.13.2.2. By Application 13.14. Thailand 13.14.1. Pricing Analysis 13.14.2. Market Share Analysis, 2022 13.14.2.1. By Treatment Methods 13.14.2.2. By Application 13.15. Indonesia 13.15.1. Pricing Analysis 13.15.2. Market Share Analysis, 2022 13.15.2.1. By Treatment Methods 13.15.2.2. By Application 13.16. Australia 13.16.1. Pricing Analysis 13.16.2. Market Share Analysis, 2022 13.16.2.1. By Treatment Methods 13.16.2.2. By Application 13.17. New Zealand 13.17.1. Pricing Analysis 13.17.2. Market Share Analysis, 2022 13.17.2.1. By Treatment Methods 13.17.2.2. By Application 13.18. GCC Countries 13.18.1. Pricing Analysis 13.18.2. Market Share Analysis, 2022 13.18.2.1. By Treatment Methods 13.18.2.2. By Application 13.19. South Africa 13.19.1. Pricing Analysis 13.19.2. Market Share Analysis, 2022 13.19.2.1. By Treatment Methods 13.19.2.2. By Application 13.20. Israel 13.20.1. Pricing Analysis 13.20.2. Market Share Analysis, 2022 13.20.2.1. By Treatment Methods 13.20.2.2. By Application 14. Market Structure Analysis 14.1. Competition Dashboard 14.2. Competition Benchmarking 14.3. Market Share Analysis of Top Players 14.3.1. By Regional 14.3.2. By Treatment Methods 14.3.3. By Application 15. Competition Analysis 15.1. Competition Deep Dive 15.1.1. Eli Lilly 15.1.1.1. Overview 15.1.1.2. Product Portfolio 15.1.1.3. Profitability by Market Segments 15.1.1.4. Sales Footprint 15.1.1.5. Strategy Overview 15.1.1.5.1. Marketing Strategy 15.1.2. Novo Nordisk 15.1.2.1. Overview 15.1.2.2. Product Portfolio 15.1.2.3. Profitability by Market Segments 15.1.2.4. Sales Footprint 15.1.2.5. Strategy Overview 15.1.2.5.1. Marketing Strategy 15.1.3. Novartis AG 15.1.3.1. Overview 15.1.3.2. Product Portfolio 15.1.3.3. Profitability by Market Segments 15.1.3.4. Sales Footprint 15.1.3.5. Strategy Overview 15.1.3.5.1. Marketing Strategy 15.1.4. Rezolute, Inc. 15.1.4.1. Overview 15.1.4.2. Product Portfolio 15.1.4.3. Profitability by Market Segments 15.1.4.4. Sales Footprint 15.1.4.5. Strategy Overview 15.1.4.5.1. Marketing Strategy 15.1.5. Eiger BioPharmaceuticals. 15.1.5.1. Overview 15.1.5.2. Product Portfolio 15.1.5.3. Profitability by Market Segments 15.1.5.4. Sales Footprint 15.1.5.5. Strategy Overview 15.1.5.5.1. Marketing Strategy 15.1.6. Zealand Pharma A/S 15.1.6.1. Overview 15.1.6.2. Product Portfolio 15.1.6.3. Profitability by Market Segments 15.1.6.4. Sales Footprint 15.1.6.5. Strategy Overview 15.1.6.5.1. Marketing Strategy 15.1.7. Hanmi Pharmaceutical Co., Ltd. 15.1.7.1. Overview 15.1.7.2. Product Portfolio 15.1.7.3. Profitability by Market Segments 15.1.7.4. Sales Footprint 15.1.7.5. Strategy Overview 15.1.7.5.1. Marketing Strategy 15.1.8. Crinetics Pharmaceuticals, Inc. 15.1.8.1. Overview 15.1.8.2. Product Portfolio 15.1.8.3. Profitability by Market Segments 15.1.8.4. Sales Footprint 15.1.8.5. Strategy Overview 15.1.8.5.1. Marketing Strategy 15.1.9. AmideBio LLC 15.1.9.1. Overview 15.1.9.2. Product Portfolio 15.1.9.3. Profitability by Market Segments 15.1.9.4. Sales Footprint 15.1.9.5. Strategy Overview 15.1.9.5.1. Marketing Strategy 15.1.10. Xeris Pharmaceuticals, Inc 15.1.10.1. Overview 15.1.10.2. Product Portfolio 15.1.10.3. Profitability by Market Segments 15.1.10.4. Sales Footprint 15.1.10.5. Strategy Overview 15.1.10.5.1. Marketing Strategy 16. Assumptions & Acronyms Used 17. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Treatment Methods, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Application, 2018 to 2033 Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Treatment Methods, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Application, 2018 to 2033 Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 8: Latin America Market Value (US$ Million) Forecast by Treatment Methods, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Application, 2018 to 2033 Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 11: Europe Market Value (US$ Million) Forecast by Treatment Methods, 2018 to 2033 Table 12: Europe Market Value (US$ Million) Forecast by Application, 2018 to 2033 Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Asia Pacific Market Value (US$ Million) Forecast by Treatment Methods, 2018 to 2033 Table 15: Asia Pacific Market Value (US$ Million) Forecast by Application, 2018 to 2033 Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: MEA Market Value (US$ Million) Forecast by Treatment Methods, 2018 to 2033 Table 18: MEA Market Value (US$ Million) Forecast by Application, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Treatment Methods, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Application, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 7: Global Market Value (US$ Million) Analysis by Treatment Methods, 2018 to 2033 Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment Methods, 2023 to 2033 Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment Methods, 2023 to 2033 Figure 10: Global Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 11: Global Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 12: Global Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 13: Global Market Attractiveness by Treatment Methods, 2023 to 2033 Figure 14: Global Market Attractiveness by Application, 2023 to 2033 Figure 15: Global Market Attractiveness by Region, 2023 to 2033 Figure 16: North America Market Value (US$ Million) by Treatment Methods, 2023 to 2033 Figure 17: North America Market Value (US$ Million) by Application, 2023 to 2033 Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 22: North America Market Value (US$ Million) Analysis by Treatment Methods, 2018 to 2033 Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment Methods, 2023 to 2033 Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment Methods, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 28: North America Market Attractiveness by Treatment Methods, 2023 to 2033 Figure 29: North America Market Attractiveness by Application, 2023 to 2033 Figure 30: North America Market Attractiveness by Country, 2023 to 2033 Figure 31: Latin America Market Value (US$ Million) by Treatment Methods, 2023 to 2033 Figure 32: Latin America Market Value (US$ Million) by Application, 2023 to 2033 Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment Methods, 2018 to 2033 Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment Methods, 2023 to 2033 Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment Methods, 2023 to 2033 Figure 40: Latin America Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 41: Latin America Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 43: Latin America Market Attractiveness by Treatment Methods, 2023 to 2033 Figure 44: Latin America Market Attractiveness by Application, 2023 to 2033 Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 46: Europe Market Value (US$ Million) by Treatment Methods, 2023 to 2033 Figure 47: Europe Market Value (US$ Million) by Application, 2023 to 2033 Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 52: Europe Market Value (US$ Million) Analysis by Treatment Methods, 2018 to 2033 Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment Methods, 2023 to 2033 Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment Methods, 2023 to 2033 Figure 55: Europe Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 56: Europe Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 57: Europe Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 58: Europe Market Attractiveness by Treatment Methods, 2023 to 2033 Figure 59: Europe Market Attractiveness by Application, 2023 to 2033 Figure 60: Europe Market Attractiveness by Country, 2023 to 2033 Figure 61: Asia Pacific Market Value (US$ Million) by Treatment Methods, 2023 to 2033 Figure 62: Asia Pacific Market Value (US$ Million) by Application, 2023 to 2033 Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033 Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Treatment Methods, 2018 to 2033 Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment Methods, 2023 to 2033 Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment Methods, 2023 to 2033 Figure 70: Asia Pacific Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 73: Asia Pacific Market Attractiveness by Treatment Methods, 2023 to 2033 Figure 74: Asia Pacific Market Attractiveness by Application, 2023 to 2033 Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033 Figure 76: MEA Market Value (US$ Million) by Treatment Methods, 2023 to 2033 Figure 77: MEA Market Value (US$ Million) by Application, 2023 to 2033 Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 82: MEA Market Value (US$ Million) Analysis by Treatment Methods, 2018 to 2033 Figure 83: MEA Market Value Share (%) and BPS Analysis by Treatment Methods, 2023 to 2033 Figure 84: MEA Market Y-o-Y Growth (%) Projections by Treatment Methods, 2023 to 2033 Figure 85: MEA Market Value (US$ Million) Analysis by Application, 2018 to 2033 Figure 86: MEA Market Value Share (%) and BPS Analysis by Application, 2023 to 2033 Figure 87: MEA Market Y-o-Y Growth (%) Projections by Application, 2023 to 2033 Figure 88: MEA Market Attractiveness by Treatment Methods, 2023 to 2033 Figure 89: MEA Market Attractiveness by Application, 2023 to 2033 Figure 90: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports
